Vaccines show promise in treating Ebola

Two experimental vaccines against the deadly Ebola virus ravaging West Africa could be available as soon as November. Ebola cAd3 and VSV-EBOV would first be given to health care workers most at risk

immune system to fight viral infection



Johnson Johnson © Crucell

National Microbiology Laboratory

VSV-EBOV: Developed by Canada's National Microbiology Laboratory. 800 doses of vaccine donated to World Health Organization

Vaccine based on weakened strains of *vesicular stomatitis virus*, a common animal pathogen. Glycoprotein of VSV is replaced with Ebola GP. Protects both before and after exposure. *Profectus Biosciences* is also developing a VSV vaccine

TKM-Ebola:

Tekmira vaccine gave 100% protection in non-human primates to otherwise lethal dose of Zaire Ebola virus

Vaccine uses RNA interference
– known as RNAi – which
silences disease by causing
genes to block Ebola replication
within cells of infected person

Prime-boost vaccine:

Netherlands-based *Crucell* and Denmark-based *Bavarian Nordic*, (J&J's vaccine division) are working with NIAID to produce a two-shot, prime-boost vaccine

First shot uses adenovirusbased vaccine to get harmless Ebola gene into cells to prime immune system. Second shot contains smallpox-based vaccine which boosts immune response

ZMapp: Vaccine developed by Mapp Biopharmaceutical



© GRAPHIC NEWS

has successfully treated five of seven Ebola victims – two fatalities

Cocktail of three genetically modified mouse *monoclonal* antibodies – molecules that neutralize GP protein on surface of Fbola virus